The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta‐cell mass and function in vitro
Diabetes, Obesity and Metabolism · 2024-09 · 26 (9) · 3606-3617
DOI: 10.1111/dom.15701 ↗At a glance
Journal article in Diabetes, Obesity and Metabolism, 2024-09. Written by Klaudia Toczyska and 8 co-authors. Institution: Department of Diabetes, School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences & Medicine, King's College London, Lon…. Major MEDLINE topics: Paroxetine, Sertraline, Selective Serotonin Reuptake Inhibitors, Insulin-Secreting Cells. Cited 5 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY 4.0). Funded by: Wellcome Trust, Medical Research Council.
Abstract (original language)
Aims
To investigate the effects of the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine at therapeutically relevant concentrations on beta‐cell mass and function.
Methods
Viability was quantified in mouse insulinoma (MIN6) beta cells and mouse islets after 48‐h exposure to sertraline (1–10 μM) or paroxetine (0.01–1 μM) using the Trypan blue exclusion test. The effects of therapeutic concentrations of these SSRIs on insulin secretion were determined by static incubation and perifusion experiments, while islet apoptosis was investigated by Caspase‐Glo 3/7 assay, TUNEL staining and quantitative PCR analysis. Finally, proliferation of MIN6 and mouse islet beta cells was assessed by bromodeoxyuridine (BrdU) enzyme‐linked immunosorbent assay and immunofluorescence.
Results
Sertraline (0.1–1 μM) and paroxetine (0.01–0.1 μM) were well tolerated by MIN6 beta cells and islets, whereas 10 μM sertraline and 1 μM paroxetine were cytotoxic. Exposure to 1 μM sertraline and 0.1 μM paroxetine significantly potentiated glucose‐stimulated insulin secretion from mouse and human islets. Moreover, they showed protective effects against cytokine‐ and palmitate‐induced apoptosis of islets, they downregulated cytokine‐induced Stat1 and Traf1 mRNA expression, and they significantly increased proliferation of mouse beta cells.
Conclusions
Our data demonstrate that sertraline and paroxetine act directly on beta cells to enhance glucose‐stimulated insulin secretion and stimulate beta‐cell mass expansion by increasing proliferation and decreasing apoptosis. These drugs are therefore likely to be appropriate for treating depression in people with type 2 diabetes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Diabetes, School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
ORCID profiles: Klaudia Toczyska, Naila Haq, Zekun Lyu, Gavin Bewick, Hannah Rosa, Bo Liu, Shanta Jean Persaud
Funding
- Wellcome Trust
- Medical Research Council
Cite
APA
Toczyska, K., Haq, N., Lyu, Z., Bewick, G., Zhao, M., Rosa, H., Starikova, J., Liu, B., & Persaud, S. J. (2024). The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta‐cell mass and function in vitro. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15701
Vancouver
Toczyska K, Haq N, Lyu Z, Bewick G, Zhao M, Rosa H, et al. The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta‐cell mass and function in vitro. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15701
BibTeX
@article{Toczyska2024,
author = {Toczyska, Klaudia and Haq, Naila and Lyu, Zekun and Bewick, Gavin and Zhao, Min and Rosa, Hannah and Starikova, Jessica and Liu, Bo and Persaud, Shanta Jean},
title = {The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta‐cell mass and function in vitro},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15701}
}
EUVIMED